Low Valuations and Improving Earnings Support a Re-rating of Japanese Pharmaceuticals
AI summary card
Low Valuations and Improving Earnings Support a Re-rating of Japanese Pharmaceuticals
JPMorgan believes the Japanese pharmaceutical sector stabilized after April–June earnings, and expectations for full-year guidance upgrades, low valuations, and underperformance versus U.S. and European sectors could together drive a sector re-rating.
- From August 10 to 14, the pharmaceutical sector was flat, while TOPIX rose 3.0%.
- Analysts expect multiple companies may raise full-year guidance during the July–September earnings season, while sector valuations remain low.
- Sumitomo Pharma (4506) rebounded on solid first-quarter results and expectations for multiple October–December catalysts; analysts consider this move reasonable.
- The pullback in Otsuka Holdings (4578) following favorable two-year Voyxact eGFR data is viewed as a buying opportunity, as earnings momentum, valuation, and medium- to long-term growth potential remain supportive.
Report interpretation
Overview
This report is a weekly review of the Japanese pharmaceutical industry, covering sector performance from August 10 to 14, 2026, April–June earnings feedback, valuations, the event calendar, and U.S. prescription trends. It concludes that sector share prices are stabilizing after earnings releases, creating a basis for re-rating.
Core views
The Japanese pharmaceutical sector may still be influenced in the short term by trends in AI- and semiconductor-related stocks, but fundamental improvement is more important. Analysts expect some companies to raise full-year guidance during July–September earnings; with valuations still low and the sector lagging U.S. and European pharmaceutical peers, re-rating momentum may gradually strengthen. At the stock level, the report favors Sumitomo Pharma (4506) for its earnings and subsequent catalysts, and also considers Otsuka Holdings (4578)'s recent pullback a buying opportunity.
Analysis framework
Analysis combines comparisons of April–June results with market expectations, sector and stock relative returns, domestic and international valuation metrics, earnings growth and yield data, event catalyst calendars, and U.S. prescription volume (TRx) trends for key drugs.
Methodology notes
Compares actual operating profit performance, progress versus expectations, and share-price reactions after earnings releases.
Used to assess the impact of April–June earnings on full-year earnings expectations and share prices.
References earnings growth, PEG, dividend yield, free cash flow yield, and overseas peer valuations.
Used to assess whether Japanese pharmaceutical stocks are undervalued and their re-rating potential relative to U.S. and European peers.
Tracks changes in U.S. prescription volumes for key drugs and competitors.
Used to monitor product demand, the competitive landscape, and potential revenue momentum.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- Otsuka Holdings (4578)Key covered stock, rated OW
- Strengths
- Voyxact's medium- to long-term profit growth potential, solid earnings momentum, and valuation that remains broadly in line with the sector average. zipalertinib met the primary progression-free survival endpoint in the interim analysis of the Phase III REZILIENT3 trial.
- Weaknesses
- The share price had previously risen on the two-year Voyxact eGFR data and has recently pulled back amid profit-taking.
- Comparison
- Valuation is broadly in line with the sector average; year-to-date gain of 35.6% outperforms the pharmaceutical sector's -0.3%.
- Risks
- Risks related to subsequent clinical trial data, commercialization execution, competing drugs, and valuation compression.
- Sumitomo Pharma (4506)Key covered stock, rated OW
- Strengths
- Solid first-quarter earnings and multiple expected catalysts in October–December; the first patient has received subretinal implantation in a Phase I/II trial of an iPS cell-derived allogeneic retinal sheet for retinitis pigmentosa in the United States.
- Weaknesses
- The share price had previously undergone a substantial correction, falling 40.8% year to date.
- Comparison
- Rose 5.9% from August 10 to 14, outperforming the pharmaceutical sector's 0.0% weekly performance.
- Risks
- Uncertainty in clinical development, catalysts falling short of expectations, prescription trends, and earnings recovery falling short of expectations.
Key data
- Weekly Performance of the Pharmaceutical Sector0.0%From August 10 to 14, 2026, versus TOPIX at +3.0%.
- Weekly Performance of Sumitomo Pharma (4506)+5.9%One of the stronger-performing pharmaceutical stocks listed in the report over the same period.
- Weekly Performance of Otsuka Holdings (4578)-5.3%Pulled back after favorable two-year Voyxact eGFR data, partly due to profit-taking.
- Year-to-Date Performance of the Pharmaceutical Sector-0.3%TOPIX was +23.1% over the same period, indicating significant sector underperformance versus the broader market.
- Year-to-Date Performance of Otsuka Holdings (4578)+35.6%As of August 14, 2026.
- Year-to-Date Performance of Sumitomo Pharma (4506)-40.8%As of August 14, 2026.
- Otsuka Holdings (4578) Price and Rating¥12,030; OWThe price listed in the report is as of the close on August 14, 2026.
- Most Recently Disclosed Target Price for Otsuka Holdings (4578)¥16,000The rating history table shows an OW rating and a ¥16,000 target price as of August 5, 2026.
Impact & implications
If full-year guidance upgrades materialize and the valuation discount narrows, the Japanese pharmaceutical sector may experience valuation recovery relative to both the broader market and U.S. and European peers. Investors can focus on earnings upgrades, clinical data, regulatory filings, prescription volumes, and product commercialization progress; at the stock level, the report favors names with earnings resilience or clear clinical and product catalysts.
Risks
- Changes in risk appetite for AI- and semiconductor-related stocks may drive short-term volatility in the pharmaceutical sector.
- Expected full-year guidance upgrades during the July–September earnings season may fail to materialize.
- Clinical trials, regulatory approvals, and product commercialization outcomes are uncertain.
- Drug competition, changes in U.S. prescription volumes, and exchange-rate fluctuations may affect earnings expectations.
- The report discloses that J.P. Morgan has market-making, client-service, and potential investment-banking compensation relationships with Otsuka Holdings (4578) and Sumitomo Pharma (4506).
What to watch
- July–September earnings and full-year guidance revisions by Japanese pharmaceutical companies.
- Subsequent commercialization and clinical progress for Otsuka Holdings (4578)'s Voyxact, as well as further trial information on zipalertinib.
- Product, clinical, and business catalysts for Sumitomo Pharma (4506) in October–December.
- Progress of Chugai Pharmaceutical's application for an additional Tecentriq adjuvant-treatment indication for MSI-High colon cancer.
- Progress of arbitration between Nippon Shinyaku and Capricor Therapeutics regarding the U.S. sales agreement for deramiocel.
- U.S. TRx trends for key drugs and changes in the valuation gap between the Japanese pharmaceutical sector and U.S. and European peers.